13F Holdings
中文EN

CGC Canopy Growth Corp

Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1737927 · Reporting currency CAD · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY10.7%
TTM net income YoY21.3%
TTM EPS YoY66.5%
Revenue 3-yr CAGR1.0%
Net income 3-yr CAGR—

Margins

Gross margin24.4%
Operating margin-54.2%
Net margin-87.8%
FCF margin-25.8%
EBITDA margin-47.5%

Returns

ROE-39.5%
ROA-25.4%
ROIC (approx.)-20.3%
Asset turnover0.29x

Leverage & solvency

Liabilities / assets38.5%
Debt / equity0.38x
Current ratio2.82x
Interest coverage-3.69x

Cash quality & payout

Operating cash flow / net income0.27x
Accruals ratio-18.6%
Payout ratio—
Capex / revenue2.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: CAD FY20262026-03-31FY20252025-03-31FY20242024-03-31FY20232023-03-31FY20222022-03-31
Income statement
Revenue284.60M269.00M297.15M333.25M475.70M
Cost of revenue214.93M189.48M216.26M396.78M663.11M
Gross profit69.67M79.51M80.88M-63.53M-187.41M
R&D expense2.61M2.74M4.61M21.72M32.26M
SG&A expense159.98M169.63M229.43M342.52M415.44M
Operating income-161.66M-117.14M-228.71M-2.63B-1.02B
Interest expense38.19M74.57M105.35M126.16M103.94M
Pretax income-262.88M-507.76M-507.77M-3.09B-267.86M
Income tax23,0007.14M12.33M-5.73M-8.95M
Net income-262.91M-508.88M-693.68M-3.28B-310.04M
EBITDA-142.63M-95.62M-200.34M-2.57B-942.66M
EPS (basic)-0.88-4.73-9.27-70.69-7.92
EPS (diluted)-0.88-4.73-9.27-70.69-7.92
Weighted avg. shares (diluted)298.04M107.55M74.79M46.37M39.13M
Banking
Net interest income————-9.57M
Balance sheet
Cash & equivalents364.68M113.81M170.30M667.69M776.00M
Short-term investments017.66M33.16M105.53M595.65M
Receivables31.24M47.51M44.94M41.29M68.20M
Inventory110.51M96.37M77.29M83.23M204.54M
Current assets529.47M294.57M371.18M1.08B1.73B
PP&E, net316.49M293.52M320.10M471.27M942.78M
Goodwill55.69M46.04M43.24M55.69M1.81B
Intangibles92.41M87.20M104.05M160.75M252.69M
Total assets1.12B917.70M1.30B2.44B5.61B
Current liabilities158.44M103.05M334.66M803.84M213.19M
Short-term debt16.24M4.26M103.94M556.89M9.30M
Long-term debt217.12M299.81M493.29M749.99M1.49B
Total debt233.36M304.07M597.23M1.31B1.50B
Total liabilities421.14M439.13M899.76M1.68B1.98B
Shareholders' equity697.59M478.57M400.43M758.43M3.58B
Net debt-131.32M190.26M426.93M639.19M724.99M
Shares outstanding422.07M183.87M91.12M51.73M—
Cash flow statement
Operating cash flow-63.81M-165.75M-281.95M-557.55M-545.81M
Capital expenditure5.33M10.81M3.45M9.11M36.68M
Free cash flow-69.14M-176.56M-285.40M-566.66M-582.50M
Investing cash flow-21.35M-47.79M241.59M433.38M230.82M
Financing cash flow332.41M148.66M-465.06M-19.69M-45.53M
Depreciation & amortization19.03M21.52M28.38M55.58M76.14M
Stock-based compensation4.27M-4.21M14.18M25.32M46.69M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.